H.C. Wainwright analyst Patrick Trucchio lowered the firm’s price target on Gossamer Bio to $5 from $25 and keeps a Buy rating on the shares. While TORREY results were disappointing relative to high expectations, a path to potential approval in pulmonary hypertension? remains possible, Trucchio tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on GOSS:
- Gossamer Bio price target lowered to $7 from $15 at BofA
- Gossamer Bio downgraded to Underweight from Neutral at JPMorgan
- Gossamer Bio downgraded to Equal Weight from Overweight at Barclays
- Gossamer Bio downgraded to Neutral from Outperform at SMBC Nikko
- Piper says ‘Street overreacted’ to Gossamer data, seralutinib still ‘promising’